Structure−Activity Relationship and Antituberculosis Properties of 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 Inhibitors
Preprint
- 13 October 2025
- preprint
- Published by F1000 Research Ltd in VeriXiv
Abstract
No abstract availableAll Related Versions
Funding Information
- South African Medical Research Council
- Bill and Melinda Gates Foundation (OPP1066878)
- University of Capetown
- South African National Research foundation, The South African Research Chairs Initiative of the Department of Science and Innovation
- Neville Isdell
This publication has 29 references indexed in Scilit:
- Update of drug-resistant tuberculosis treatment guidelines: A turning pointInternational Journal of Infectious Diseases, 2023
- Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic targetStructure, 2021
- Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain ManagementJournal of Medicinal Chemistry, 2020
- MmpL3 inhibitors as antituberculosis drugsEuropean Journal of Medicinal Chemistry, 2020
- Structural Basis for the Inhibition of Mycobacterial MmpL3 by NITD-349 and SPIROJournal of Molecular Biology, 2020
- The quest for the holy grail: new antitubercular chemical entities, targets and strategiesDrug Discovery Today, 2020
- Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug TargetCell, 2019
- Comprehensive review of cardiovascular toxicity of drugs and related agentsMedicinal Research Reviews, 2018
- Towards a Structural View of Drug Binding to hERG K + ChannelsTrends in Pharmacological Sciences, 2017
- Application of the Pentafluorosulfanyl Group as a Bioisosteric ReplacementChemMedChem, 2017